SOURCE: SciClone Pharmaceuticals, Inc.

May 02, 2008 06:30 ET

SciClone Pharmaceuticals to Report First Quarter 2008 Results on May 8, 2008

FOSTER CITY, CA--(Marketwire - May 2, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2008 results and host a conference call on Thursday, May 8, 2008.

Management will review operating results for the first quarter 2008 and give a business update. The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's website at www.sciclone.com prior to the commencement of the conference call.

DATE:          Thursday, May 8, 2008
TIME:          11:00 a.m. ET (8:00 a.m. PT)
WEBCAST:       Live call and replay accessible at www.sciclone.com
LIVE CALL:     877-419-6600 (U.S./Canada)
               719-325-4896 (International)
REPLAY:        888-203-1112 (U.S./Canada)
               719-457-0820 (International)
               Passcode:  2400325

(Replay available from 2:00 p.m. ET on May 8, 2008 through 12:00 a.m. ET on June 6, 2008)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of hepatitis C and malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese pharmaceutical market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate Contact:
    Erin Murphy
    SciClone Pharmaceuticals, Inc.
    Email Contact
    (650) 358-3437